Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 1;10(11):e005241. doi: 10.1136/jitc-2022-005241

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Effect of Ago-125b-5p on the tumor infiltration Tregs and TNFR2 expression and on cytotoxic CD8 T cells. After treatment by Ago-125b-5p for five doses on MC38 tumor-bearing mice, the immune cells in tumor tissue were detected by flow cytometry. (A) Representative flow cytometric plot of the proportion of Tregs in CD4⁺ T cells in mouse tumor tissue after treated by Ago-125b-5p. Number shows the proportion of gated cells. (B) Representative typical histograms of TNFR2 expression in Foxp3⁺ Tregs. Number in the histogram indicates the proportion of gated cells. (C) Summary of the proportion of FoxP3⁺ Tregs in CD4 populations as shown in figure part A. (D) The expression of TNFR2-expressing cells in Tregs. (E) The concentration of soluble TNFR2 levels in serum after treated by Ago-125b-5p. (F) The mean fluorescence intensity (MFI) of TNFR2 expression by tumor-infiltrating CD8⁺ T cells. (G) Representative flow cytometric plot of the proportion of IFNγ⁺CD8⁺ T cells in CD8⁺ T cells in mouse tumor tissue after treated by Ago-125b-5p. Number shows the proportion of gated cells. (H) Summary of the proportion of IFNγ⁺CD8⁺ T cells in CD8⁺ T cells. The summarized data shown in figure parts C, D, E, F and H were displayed as mean±SEM, n=5 mice of each group. All data were representatives of three separate experiments. By comparison with Ago- NC, *p<0.05, **p<0.01, ***p<0.001 (Student’s t-test). TNFR2, tumor necrosis factor receptor type 2.